Genomic Health (GHDX) Prostate Test Shows Encouraging Signs - Analyst
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
BofA/Merrill Lynch Downgrades Genomic Health Inc. (GHDX) to Neutral
June 18, 2013 6:58 AM EDTBofA/Merrill Lynch downgraded Genomic Health Inc. (NASDAQ: GHDX) from Buy to Neutral.
For an analyst ratings summary and ratings history on Genomic Health Inc. click here. For more ratings news on... More
